Mednet Logo
SpecialtiesRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

In what clinical situations would you favor IM methylprednisolone over a short oral prednisone taper for managing an RA flare?

3 Answers

Mednet Member
Mednet Member
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

I am not an RA expert; however, I am well-versed in the use of IM steroids for flares.After Dr. Petri's FLOAT study in SLE (Danowski et al., PMID 16395750), we have utilized IM steroids instead of daily PO prednisone as our "go-to" treatment of choice as much as we can over Medrol dose packs and QD ...

Would you add romosozumab to denosumab for a year or switch to romosozumab for a year in a patient who fractures on long term denosumab therapy?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Icahn School of Medicine at Mount Sinai

My preference, if insurance was not an obstacle, would be to add romo rather than switch. The data are limited and certainly this is "off label" but the rationale is reasonable. Denosumab treatment leads to increased sclerostin levels which would be targeted by the addition of Romo; furthermore thi...

Does significant eosinophilia (8-44%) in a patient with suspected granulomatosis with polyangiitis (GPA) based on sinusitis, pulmonary nodules and positive PR3 change your management approach?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Massachusetts General Hospital

This is an important question because at times the distinction between GPA and EGPA can be difficult to make. In general, I would rely on clinical symptoms as a key distinguisher. For example, sinusitis in GPA differs from that of EGPA, with the former often causing crusting, erosions/necrosis on EN...

When do you consider genetic testing for autoinflammatory diseases in patients with recurrent pericarditis and fever, particularly when symptoms are highly responsive to IL-1 blockade?

2
2 Answers

Mednet Member
Mednet Member
Rheumatology · Massachusetts General Hospital

Yesterday ;-). About 10% of patients with recurrent pericarditis have genes that may increase their risk of pericarditis. If you're already managing the patient with IL-1 inhibition, I would strongly encourage you to conduct genetic testing. Just my 2 cents...

Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?

1
5 Answers

Mednet Member
Mednet Member
Rheumatology · Berkshire Health Systems

Nope. IVIG preparations contain IgG not IgA or IgM. Low serum IgA may or may not be associated with low IgA levels in mucosal surfaces leading to a risk of local infections. Low levels of one or both may be asymptomatic but in the right setting might suggest a need for evaluation of plasma cell dysc...

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

1
4 Answers

Mednet Member
Mednet Member
Rheumatology · Leiden University Medical Center

Many trials have a placebo-controlled period of 12-24 weeks. Thereafter, all patients receive active treatment. Even if the original treatment allocation remains unknown to the patient and doctor, they know that from that moment on, everyone receives active treatment. This will have an influence on ...

How do you manage patients with severe hand OA (no synovitis on exam, negative serologies) who fail to respond to NSAIDs but respond very well to oral steroids?

3
3 Answers

Mednet Member
Mednet Member
Rheumatology · Sunshine Rheumatology & Arthritis Center

I have used Hydroxychloroquine with some success and offer that to patients for a trial for 4 months if they are willing.

Is a history of Zoster ophthalmicus a contraindication to starting upadacitinib?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Legacy Devers Eye Institute

A history of HZO (herpes zoster ophthalmicus) or herpes zoster in any dermatome is a relative contraindication to the use of upadacitinib or any JAK inhibitor. HZO is often a very unpleasant disease with pain, ocular discomfort, and vision loss, so the chance of reactivation should be minimized. The...

What is your preferred first-line treatment for chronic fatigue in patients with long COVID-19?

9
9 Answers

Mednet Member
Mednet Member
Neurology · University of Minnesota

Assuming that a thorough workup for other causes of fatigue (anemia, thyroid dysfunction, sleep apnea, etc.) has been performed and is negative, no single medication has been proven by a randomized placebo-controlled trial to help chronic fatigue in PASC. Anecdotally, my colleagues who treat PASC ha...